CARsgen Therapeutics Receives Positive EMA Opinion on Orphan Drug Designation for Fully Human Anti-BCMA CAR-T Cells (CT053) for the Treatment of Multiple Myeloma
SHANGHAI, April 27, 2020 -- (Healthcare Sales & Marketing Network) -- CARsgen Therapeutics Co., Ltd., a clinical-stage biopharmaceutical company, today announced the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) adopted a ... Biopharmaceuticals, Oncology, Regulatory CARsgen Therapeutics, CAR-T, cell therapy, multiple myeloma
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Cancer & Oncology | European Medicines Agency (EMA) | Marketing | Myeloma | Pharmaceuticals